跳至主要内容
临床试验/NCT00525941
NCT00525941撤回3 期

An Exploratory Phase IIIb, Single-Blind, Outpatient Study to Assess Next-Day Functioning in Adult Primary Insomnia Patients Following the Administration of NBI-34060 Capsules During the Night

Neurocrine Biosciences8 个研究点 分布在 1 个国家开始时间: 2007年9月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
撤回
试验地点
8
主要终点
Assessments of Next-Day Function

研究概览

简要总结

NBI-34060 is an investigational (research) medication being studied in people with insomnia. The current study is designed to evaluate how people, who experience a nighttime awakening with difficulty returning to sleep, feel during the next day after dosing with NBI-34060. The study will also examine the pattern and extent of nighttime awakenings as reported by the patients, as well as and the patient's sleep experience during treatment.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 64 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • insomnia (DSM-IV diagnosed; at least one month)
  • Nocturnal awakenings
  • Usual bedtimes between 9:00PM and Midnight.
  • Bedtimes that do not vary by more than 2 hours on 5 or more nights per week.
  • A usual time in bed of 7 to 9 hours.

排除标准

  • no serious concomitant illness
  • no other condition that could interfere with sleep

结局指标

主要结局

Assessments of Next-Day Function

时间窗: daily/six weeks

次要结局

  • Quality of Life(biweekly/six weeks)

研究者

申办方类型
Industry

研究点 (8)

Loading locations...

相似试验